Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb 13;104(3):365-71.
doi: 10.1161/CIRCRESAHA.108.184044. Epub 2008 Dec 18.

Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart

Jiaxiang Qu  1 , Frank M Volpicelli, Luis I Garcia, Nefthi Sandeep, Jie Zhang, Lucrecia Márquez-Rosado, Paul D Lampe, Glenn I Fishman
Affiliations

Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart

Jiaxiang Qu et al. Circ Res. .

Abstract

Pressure overload is a common pathological insult to the heart and the resulting hypertrophy is an independent risk factor for sudden cardiac death. Gap junction remodeling (GJR) has been described in hypertrophied hearts; however, a detailed understanding of the remodeling process and its effects on impulse propagation is lacking. Moreover, there has been little progress developing therapeutic strategies to diminish GJR. Accordingly, transverse aortic banding (TAC) was performed in mice to determine the effects of progressive pathological hypertrophy on connexin (Cx)43 expression, posttranslational phosphorylation, gap junction assembly, and impulse propagation. Within 2 weeks after TAC, total and phospho-Cx43 abundance was reduced and incorporation of Cx43 into gap junctional plaques was markedly diminished. These molecular changes were associated with progressive slowing of impulse propagation, as determined by optical mapping with voltage-sensitive dyes. Treatment with the aldosterone receptor antagonist spironolactone, which has been shown to diminish sudden arrhythmic death in clinical trials, was examined for its effects on GJR. We found that spironolactone blunted the development of GJR and also potently reversed established GJR, both at the molecular and functional levels, without diminishing the extent of hypertrophy. These data suggest a potential mechanism for some of the salutary electrophysiological and clinical effects of mineralocorticoid antagonists in myopathic hearts.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Molecular and functional GJR in TAC mice. A, Representative cross-sections of hearts showing progressive hypertrophy. B, Western blot analysis demonstrating GJR. Hearts were harvested at the indicated times post-TAC and either total cellular lysates (T) or Triton X-100 insoluble pellet fractions (P) were prepared. Antibodies were directed toward the Cx43 C terminus (Cx43-C); Cx43 N terminus (Cx43-N); vinculin (Vinc); S365-phosphoCx43 (pS365); or S325/328/330-phosphoCx43 (pS325). C, Immunofluorescent staining shows progressive loss of junctional Cx43. Sections were stained with a pan-Cx43 antibody. D, Representative optical maps demonstrate progressive slowing of CV. Perfusion of 4-week post-TAC hearts with αGA resulted in additional slowing of CV. Time points include sham (S), 2 weeks (2W), 4 weeks (4W), and 8 weeks (8W) post-TAC.
Figure 2
Figure 2
Aberrant phosphorylation of Cx43 in TAC mice. Sections were prepared at the indicated time points and stained with antibodies recognizing all forms of Cx43 (Total Cx43), S365-phosphoCx43 (pS365), or S325/328/330-phosphoCx43 (pS325). Diminution of both phosphorylated forms of Cx43 is evident as early as 1 week post-TAC. Scale bar=50 μm.
Figure 3
Figure 3
Inhibition of GJR with spironolactone. Groups of mice were subjected to either sham operation (S) or TAC (T) and fed either normal chow (−SPI) or chow supplemented with spironolactone (+SPI). Analyses were performed 4 weeks after surgery. A, Northern blot analysis demonstrates no changes in Cx43 mRNA abundance. B, Western blot analysis with a panCx43 antibody demonstrates increased slow-mobility Cx43 in both S+SPI and T+SPI hearts. C, Representative immunofluorescent staining demonstrates loss of Cx43 gap junction plaques in TAC−SPI hearts but substantial improvement in mice treated with spironolactone (TAC+SPI). D, Representative optical maps from each of the 4 groups. E, Representative immunofluorescent staining in reversal experiment demonstrates improvement after 2 weeks of treatment with spironolactone. F, Representative optimal maps from reversal experiment.
Figure 4
Figure 4
Enhanced Cx43 phosphorylation with spironolactone. Sections were prepared from each of the experimental groups 4 weeks after randomization and stained with antibodies recognizing all forms of Cx43 (Total Cx43), S365-phosphoCx43 (pS365), or S325/328/330-phosphoCx43 (pS325). Representative images are shown. Reduced immunoreactive Cx43 is seen in the TAC−SPI hearts with all 3 antibodies. Spironolactone treatment partially restores the appearance of the gap junctional plaques. Scale bar=50 μm.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McLenachan JM, Dargie HJ. Left ventricular hypertrophy as a factor in arrhythmias and sudden death. Am J Hypertens. 1989;2:128–131. - PubMed
    1. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens Suppl. 1991;9:S3–S8. - PubMed
    1. Messerli FH, Ketelhut R. Left ventricular hypertrophy: an independent risk factor. J Cardiovasc Pharmacol. 1991;17(suppl 4):S59–S66. - PubMed
    1. Messerli FH, Soria F. Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death. Am J Med. 1992;93:21S–26S. - PubMed
    1. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32:1454–1459. - PubMed

Publication types